drugset / Trial / NCT04205136

Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea Patients

NCT04205136

Phase 4 Withdrawn University of Michigan
RandomizedParallel-groupDouble-blindSupportive care

Summary

The purpose of this study is to test whether Spironolactone can improve the severity of obstructive sleep apnea and improve cardiovascular biomarkers in people who are not regularly using their Positive Airway Pressure (PAP) therapy.

Timeline

Start
2022-03
Primary completion
2023-04
Completion
2023-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Spironolactone Small molecule 50 mg